InvestorsHub Logo
Followers 87
Posts 32835
Boards Moderated 1
Alias Born 12/19/2004

Re: None

Monday, 11/27/2023 9:52:26 AM

Monday, November 27, 2023 9:52:26 AM

Post# of 30373
Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)

PUBLISHED
NOV 27, 2023 8:00AM EST

https://www.nasdaq.com/press-release/seelos-therapeutics-announces-the-selection-of-sls-002-intranasal-racemic-ketamine
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SEEL News